UNSPSC 51142530: Lisuride

This classification denotes an antiparkinsonian agent with the molecular formula C20H26N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E0QN3D755O, chemically known as 3-(9,10-didehydro-6-methylergolin-8alpha-yl)-1,1-diethylurea but generally known as lisuride, which bears US NIH Compound Identifier 28864. European Medicines Agency schedules Lisuride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08535MIG.

UNSPSC 51142530 Lisuride, a Commodity code, covers pharmaceutical products that state and local governments procure through direct supply arrangements, cooperative purchasing programs, and health agency contracts. The actual buying under this code encompasses generic pharmaceuticals, over-the-counter products, and specialized medications such as naloxone distributed through county health departments and state pharmacy benefit programs. State and local issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances administering pharmaceutical contracts on behalf of multiple jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across participating states including Oregon).

Recent activity spans Florida, Texas, and the upper Midwest. Seminole County issued an IFB (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, Florida; the contract carries a two-year initial term with one-year renewal option and includes E-Verify compliance and drug-free workplace certification requirements. The Texas Health and Human Services Commission posted a Request for Information (HHS0017013, response due April 3, 2026) to explore vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued an RFP (S1070000015802, proposals due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), with awards effective July 1, 2026, and evaluation weighted 75 percent on price competitiveness. Vendors responding to state and local pharmaceutical solicitations must comply with FDA requirements, Good Manufacturing Practices (cGMP), the Drug Supply Chain Security Act, and maintain specific insurance coverage including commercial general liability and professional liability.